Re-Pharm Identifies Novel Anti-Inflammatory Activity for Existing Compound
News Feb 11, 2015
Re-Pharm has announced the identification of RP0217 as an effective new anti-inflammatory agent.
RP0217 is an existing drug which is widely prescribed for non-inflammatory conditions. The identification of this novel anti-inflammatory activity creates the opportunity to develop new non-steroidal approaches to the treatment of a variety of disease indications.
“Re-Pharm is dedicated to re-purposing compounds to address areas of unmet medical need,” says Dr Alan Rothaul, CSO at Re-Pharm. “Our streamlined method made it possible to move efficiently through pharmacological assessment, computational chemistry work and initial testing in order to demonstrate novel anti-inflammatory activity for an existing drug.”
“We are delighted with the discovery of RP0217 and look forward to its progression through clinical trials,” says Dr Robert Scoffin, CEO at Re-Pharm. “The filing of our first patents represents a significant validation of Re-Pharm’s approach to re-profiling and I look forward to many similar future successes.”
Concept Life Sciences and Alderley Analytical Partner to provide Bioanalytical and DMPK ServicesNews
Companies announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.READ MORE
Arrow Poison Potential Male Birth ControlNews
Women have many options for oral contraceptives that are safe, effective and reversible, but despite decades of research, men have none. Now, scientists report a rat study that shows they finally have a good lead for a male birth control pill. It's based on ouabain, a plant extract that African warriors and hunters traditionally used as a heart-stopping poison on their arrows.READ MORE